Pfizer (PFE)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
$29.95+1.70%
Close 2026-10-29 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-29
Research Workspace
Put PFE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Full-year 2026 revenue in range $59.5 to $62.5 billion: Revenue guidance: $60.5B to $62.5B.
View ThesisRevenue is contracting — down about 0% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 15%.
View QualityManagement screens strong on capital allocation, earnings delivery, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskPfizer's investment case rests on its research pipeline offsetting patent-expiration pressure. Revenue growth slowed from 5% in Q1 FY2026 to 3% in Q2, despite an earnings beat. Q2 non-GAAP EPS beat consensus by 13.2%. Pfizer trades at 10× P/E versus a 16× peer median; expectations look modest versus our view. Full-year 2026 revenue guidance of $60.5 billion to $62.5 billion puts the primary pillar under pressure. Our model puts the next-quarter miss probability near 11%. Peer multiples imply a price about 6% above where it trades; the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. PFE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 29 analysts currently covering PFE (as of Oct 2026).
Based on 4 Wall Street analysts offering 12-month price targets for PFE in the last 4 months.
Continue this research
Compare PFE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PFE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put PFE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Invest in R&D pipeline with ~20 pivotal study starts in 2026
A Phase 3 cancer-trial win supports pipeline progress, but the headline gives no trial or result details.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $29.95
The last 12 months of price, then the range of analyst 12-month targets from today’s $29.95.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Invest in R&D pipeline with ~20 pivotal study starts in 2026
Phase 2 results provide pipeline evidence, but remain early-stage and do not confirm pivotal-study progress.
Growth concerns could impact full-year 2026 financial guidance.
Threatens: Achieve $5.7 billion net cost savings by 2027
Job cuts may hinder achieving cost savings target.
Threatens: Achieve $5.7 billion net cost savings by 2027
Job cuts may hinder achieving cost savings target.
Partnership supports R&D pipeline and community engagement.
Legal issues could impact financial guidance and reputation.
Advances: Invest in R&D pipeline with ~20 pivotal study starts in 2026
Positive results support R&D pipeline investment objective.
